A Summary of Current Guidelines and Future Directions for Medical Management and Monitoring of Patients with Cystinuria

• Published in: Healthcare (Basel) Vol. 11; no. 5; p. 674
• Main Authors: Azer, Sarah M, Goldfarb, David S
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.02.2023; MDPI
• Subjects: Amino acids; Aminoaciduria, Renal; Care and treatment; Clinical significance; Creatinine; cystine/metabolism; Density; Diagnosis; Drug dosages; Drug therapy; genetics; Health surveillance; kidney calculi; Kidney diseases; Kidney stones; Mutation; nephrolithiasis; Patients; Proteins; Quality of life; renal aminoaciduria; Sodium; Urine; urolithiasis; United States; United States > US; kidney calculi; nephrolithiasis; urolithiasis; genetics; cystine/metabolism; renal aminoaciduria
• ISSN: 2227-9032; 2227-9032
• DOI: 10.3390/healthcare11050674

Cystinuria is the most common genetic cause of recurrent kidney stones. As the result of a genetic defect in proximal tubular reabsorption of filtered cystine, increased urine levels of the poorly soluble amino acid result in recurrent cystine nephrolithiasis. Recurrent cystine stones not only adversely affect the quality of patients suffering from cystinuria but also may result in chronic kidney disease (CKD) from recurrent renal injury. Thus, the mainstay of medical management revolves around prevention of stones. Recently published consensus statements on guidelines for managing cystinuria were released from both the United States and Europe. The purpose of this review is to summarize guidelines for medical management of patients with cystinuria, to provide new insight into the utility and clinical significance of cystine capacity-an assay for monitoring cystinuria, and to discuss future directions for research on treatment of cystinuria. We discuss future directions, including the potential use of cystine mimetics, gene therapy, V2-receptor blockers, and SGLT2 inhibitors, topics which have not appeared in more recent reviews. It is notable that in the absence of randomized, controlled trials, the recommendations cited here and in the guidelines are based on our best understanding of the disorder's pathophysiology, observational studies, and clinical experience.